







Lab No. : SLK/25-03-2023/SR7450761

Patient Name : HARENDRA KUMAR

Age : 36 Y 8 M 24 D

Gender: M

Lab Add. : Newtown, Kolkata-700156

Ref Dr. : Dr.MEDICAL OFFICER **Collection Date:** 25/Mar/2023 11:07AM

Report Date : 25/Mar/2023 02:52PM



Test Name	Result	Unit	Bio Ref. Interval	Method
SODIUM, BLOOD , GEL SERUM				
SODIUM,BLOOD	143	mEq/L	132 - 146 mEq/L	ISE INDIRECT
*CHLORIDE, BLOOD , .				
CHLORIDE,BLOOD	107	mEq/L	99-109 mEq/L	ISE INDIRECT
THYROID PANEL (T3, T4, TSH), GEL SER	RUM			
T3-TOTAL (TRI IODOTHYRONINE)	1.06	ng/ml	0.60-1.81 ng/ml	CLIA
T4-TOTAL (THYROXINE)	11.5	μg/dL	3.2-12.6 μg/dL	CLIA
TSH (THYROID STIMULATING HORMONE) 1.24	μIU/mL	0.55-4.78 μIU/mL	CLIA

Serum TSH levels exhibit a diurnal variation with the peak occurring during the night and the nadir, which approximates to 50% of the peak value, occurring between 1000 and 1600 hours.[1,2] References:

- 1. Bugalho MJ, Domingues RS, Pinto AC, Garrao A, Catarino AL, Ferreira T, Limbert E and Sobrinho L. Detection of thyroglobulin mRNA transcripts in peripheral blood of
- individuals with and without thyroid glands: evidence for thyroglobulin expression by blood cells. Eur J Endocrinol 2001;145:409-13.
- 2. Bellantone R, Lombardi CP, Bossola M, Ferrante A,Princi P, Boscherini M et al. Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrence varies according to the histologic type: results of a prospective study. Cancer 2001;92:2273-9.

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:

FIRST TRIMESTER: $0.10-3.00~\mu$ IU/mL SECOND TRIMESTER: 0.20 -3.50 μ IU/mL THIRD TRIMESTER: 0.30 -3.50 μ IU/mL

References:

- 1. Erik K. Alexander, Elizabeth N. Pearce, Gregory A. Brent, Rosalind S. Brown, Herbert Chen, Chrysoula Dosiou, William A. Grobman, Peter Laurberg, John H. Lazarus, Susan J. Mandel, Robin P. Peeters, and Scott Sullivan. Thyroid. Mar 2017.315-389. http://doi.org/10.1089/thy.2016.0457
- 2. Kalra S, Agarwal S, Aggarwal R, Ranabir S. Trimester-specific thyroid-stimulating hormone: An indian perspective. Indian J Endocr Metab 2018;22:1-4.

GLUCOSE, FASTING, BLOOD, NAF PLASMA

GLUCOSE, FASTING 74

mg/dL

Impaired Fasting-100-125 Gluc Oxidase Trinder .~Diabetes- >= 126.~Fasting is defined as no caloric intake for at least 8 hours.









Lab No. : SR7450761 Name : HARENDRA KUMAR Age/G : 36 Y 8 M 24 D / M Date : 25-03-2023

In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

Reference

ADA Standards of Medical Care in Diabetes – 2020. Diabetes Care Volume 43, Supplement 1.

POTASSIUM, BLOOD, GEL SERUM

POTASSIUM,BLOOD 4.80 mEq/L 3.5-5.5 mEq/L

ISE INDIRECT

Dr NEEPA CHOWDHURY MBBS MD (Biochemistry) Consultant Biochemist

Lab No. : SLK/25-03-2023/SR7450761 Page 2 of 9









Lab No. : SR7450761 Nam	e : HARENDRA KUMAR		Age/G: 36 Y 8 M 24 D / M	Date: 25-03-2023
SGPT/ALT, GEL SERUM				
SGPT/ALT	88	U/L	7-40 U/L	Modified IFCC
UREA,BLOOD , GEL SERUM	19.3	mg/dL	19-49 mg/dL	Urease with GLDH
PHOSPHORUS-INORGANIC, BLC	OOD , GEL SERUM			
PHOSPHORUS-INORGANIC,BLOO	D 3.4	mg/dL	2.4-5.1 mg/dL	Phosphomolybdate/UV
TOTAL PROTEIN [BLOOD] ALB:0	GLO RATIO,			
TOTAL PROTEIN	7.40	g/dL	5.7-8.2 g/dL	BIURET METHOD
ALBUMIN	4.5	g/dL	3.2-4.8 g/dL	BCG Dye Binding
GLOBULIN	2.90	g/dl	1.8-3.2 g/dl	Calculated
AG Ratio	1.55		1.0 - 2.5	Calculated
SGOT/AST, GEL SERUM				
SGOT/AST	42	U/L	13-40 U/L	Modified IFCC
CREATININE, BLOOD	0.88	mg/dL	0.7-1.3 mg/dL	Jaffe, alkaline picrate, kinetic
URIC ACID, BLOOD , GEL SERUM	1			
URIC ACID,BLOOD	8.60	mg/dL	3.5-7.2 mg/dL	Uricase/Peroxidase
LIPID PROFILE, GEL SERUM				
CHOLESTEROL-TOTAL	135	mg/dL	Desirable: < 200 mg/dL Borderline high: 200-239 mg/dL High: > or =240 mg/dL	Enzymatic
TRIGLYCERIDES	76	mg/dL	Normal:: < 150, BorderlineHigh::150-199, High:: 200-499, VeryHigh::>500	GPO-Trinder
HDL CHOLESTEROL	26	mg/dl	< 40 - Low 40-59- Optimum 60 - High	Elimination/catalase
LDL CHOLESTEROL DIRECT	104	mg/dL	OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dl High: 160-189 mg/dL, Very high: >=190 mg/dL	Elimination / Catalase
VLDL	5	mg/dl	< 40 mg/dl	Calculated
CHOL HDL Ratio	5.2		LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	Calculated

Reference: National Cholesterol Education Program. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. May 16 2001;285(19):2486-97.

ALKALINE PHOSPHATASE , $GEL\ SERUM$

ALKALINE PHOSPHATASE 91 U/L 46-116 U/L IFCC standardization

URIC ACID, URINE, SPOT URINE

URIC ACID, SPOT URINE **35.00** mg/dL 37-92 mg/dL URICASE

ESTIMATED TWICE

CALCIUM, BLOOD

CALCIUM,BLOOD 9.00 mg/dL 8.7-10.4 mg/dL Arsenazo III

Lab No. : SLK/25-03-2023/SR7450761 Page 3 of 9









Lab No. : SR7450761 Name : HARENDRA KUMAR Age/G : 36 Y 8 M 24 D / M Date : 25-03-2023

BILIRUBIN (DIRECT) , GEL SERUM

BILIRUBIN (DIRECT) 0.20 mg/dL <0.2 mg/dL Vanadate oxidation

BILIRUBIN (TOTAL), GEL SERUM

BILIRUBIN (TOTAL)

0.80 mg/dL

0.3-1.2 mg/dL

Vanadate oxidation

Dr. SUPARBA CHAKRABARTI MBBS, MD(BIOCHEMISTRY) Consultant Biochemist

Lab No. : SLK/25-03-2023/SR7450761 Page 4 of 9









Lab No. : SR7450761	Name : HAREN	DRA KUMAR		Age/G: 36 Y 8 M 24 D / M	Date : 25-03-2023
CBC WITH PLATELET (THRO	мвосуте) со	UNT , EDTA WHOL	E BLOOD		
HEMOGLOBIN		14.4	g/dL	13 - 17	PHOTOMETRIC
WBC	(6.0	*10^3/µL	4 - 10	DC detection method
RBC		4.81	*10^6/µL	4.5 - 5.5	DC detection method
PLATELET (THROMBOCYTE) COUNT	214	*10^3/µL	150 - 450*10^3/μL	DC detection method/Microscopy
DI FFERENTI AL COUNT					
NEUTROPHILS		64	%	40 - 80 %	Flowcytometry/Microscopy
LYMPHOCYTES	:	28	%	20 - 40 %	Flowcytometry/Microscopy
MONOCYTES		06	%	2 - 10 %	Flowcytometry/Microscopy
EOSINOPHILS	(02	%	1 - 6 %	Flowcytometry/Microscopy
BASOPHILS	(00	%	0-0.9%	Flowcytometry/Microscopy
CBC SUBGROUP					
HEMATOCRIT / PCV		44.8	%	40 - 50 %	Calculated
MCV	•	93.1	fl	83 - 101 fl	Calculated
MCH	:	30.0	pg	27 - 32 pg	Calculated
MCHC	:	32.2	gm/dl	31.5-34.5 gm/dl	Calculated
RDW - RED CELL DISTRIBUT	TION WIDTH	16.0	%	11.6-14%	Calculated
PDW-PLATELET DISTRIBUT	ION WIDTH	25.6	fL	8.3 - 25 fL	Calculated
MPV-MEAN PLATELET VOLU	JME	11.8		7.5 - 11.5 fl	Calculated
ESR (ERYTHROCYTE SEDIM	ENTATION RAT	「E) , EDTA WHOLE	BLOOD		
1stHour		19	mm/hr	0.00 - 20.00 mm/hr	Westergren
URINE ROUTINE ALL, ALL,	URINE				
PHYSI CAL EXAMI NATI ON	<u>/</u>				
COLOUR	i	PALE YELLOW			
APPEARANCE	9	SLIGHTLY HAZY			
CHEMI CAL EXAMI NATI ON	<u>v</u>				
pH	Į.	5.0		4.6 - 8.0	Dipstick (triple indicator method)
SPECIFIC GRAVITY	:	1.015		1.005 - 1.030	Dipstick (ion concentration method)
PROTEIN	I	NOT DETECTED		NOT DETECTED	Dipstick (protein error of pH indicators)/Manual
GLUCOSE	ı	NOT DETECTED		NOT DETECTED	Dipstick(glucose-oxidase-peroxidase method)/Manual
KETONES (ACETOACETIC A ACETONE)	CID, I	NOT DETECTED		NOT DETECTED	Dipstick (Legals test)/Manual
BLOOD	Ī	NOT DETECTED		NOT DETECTED	Dipstick (pseudoperoxidase reaction)
BILIRUBIN	Ī	NEGATIVE		NEGATIVE	Dipstick (azo-diazo reaction)/Manual
UROBILINOGEN	Ī	NEGATIVE		NEGATIVE	Dipstick (diazonium ion reaction)/Manual
NITRITE	I	NEGATIVE		NEGATIVE	Dipstick (Griess test)
LEUCOCYTE ESTERASE	I	NEGATIVE		NEGATIVE	Dipstick (ester hydrolysis reaction)
MI CROSCOPI C EXAMINAT	TI ON				
LEUKOCYTES (PUS CELLS)	(0-1	/hpf	0-5	Microscopy
EPITHELIAL CELLS	(0-1	/hpf	0-5	Microscopy
RED BLOOD CELLS	i	NOT DETECTED	/hpf	0-2	Microscopy
		NOT DETECTED		NOT DETECTED	Microscopy
CAST	!	TO F DE LECTED			
CAST CRYSTALS		NOT DETECTED		NOT DETECTED	Microscopy
	ı			NOT DETECTED NOT DETECTED	Microscopy Microscopy

Lab No. : SLK/25-03-2023/SR7450761 Page 5 of 9









Lab No.: SR7450761 Name: HARENDRA KUMAR Age/G: 36 Y 8 M 24 D / M Date: 25-03-2023

Note:

- 1. All urine samples are checked for adequacy and suitability before examination.
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.
- 8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

 ABO
 A
 Gel Card

 RH
 POSITIVE
 Gel Card

TECHNOLOGY USED: GEL METHOD

ADVANTAGES:

- · Gel card allows simultaneous forward and reverse grouping.
- · Card is scanned and record is preserved for future reference.
- · Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

DR. NEHA GUPTA MD, DNB (Pathology) Consultant Pathologist

Lab No. : SLK/25-03-2023/SR7450761 Page 6 of 9









Lab No.: SR7450761 Name: HARENDRA KUMAR Age/G: 36 Y 8 M 24 D / M Date: 25-03-2023

PDF Attached

GLYCATED HAEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C) 4.9

***FOR BIOLOGICAL REFERENCE INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL INFORMATION ***

HPLC 30.0 mmol/mol HbA1c (IFCC)

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Low risk / Normal / non-diabetic : <5.7% (NGSP) / < 39 mmol/mol (IFCC) Pre-diabetes/High risk of Diabetes : 5.7%- 6.4% (NGSP) / 39 - < 48 mmol/mol (IFCC) Diabetics-HbA1c level : >/= 6.5% (NGSP) / > 48 mmol/mol (IFCC)

Analyzer used: Bio-Rad-VARIANT TURBO 2.0

Method: HPLC Cation Exchange

Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.
- Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B₁₂/ folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

- Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
- Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

GLUCOSE, PP, BLOOD, NAF PLASMA

GLUCOSE, PP 95 mg/dL Impaired Glucose Tolerance-140 Gluc Oxidase Trinder to 199.

Diabetes>= 200.

The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water. In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples.

ADA Standards of Medical Care in Diabetes - 2020. Diabetes Care Volume 43, Supplement 1.

DR. ANANNYA GHOSH MBBS, MD (Biochemistry)

Consultant Biochemist

Page 7 of 9 Lab No. SLK/25-03-2023/SR7450761



Lab No. : SLK/25-03-2023/SR7450761

Patient Name : HARENDRA KUMAR Ref Dr. : Dr.MEDICAL OFFICER

Age : 36 Y 8 M 24 D

Gender : M Report Date : 25/Mar/2023 05:35PM



DEPARTMENT OF CARDIOLOGY REPORT OF E.C.G.

Lab Add.

Collection Date:

D.4.74		
DATA HEART RATE	68	Bpm
PR INTERVAL	160	Ms
QRS DURATION	90	Ms
QT INTERVAL	374	Ms
QTC INTERVAL	402	Ms
AXIS P WAVE	-26	Degree
QRS WAVE	42	Degree
T WAVE IMPRESSION	16 :	Degree Normal sinus rhythm, within normal limits.

Dr. KUNAL BISWAS

MBBS, PG Diploma in Clinical Cardiology Advance Echo training ,Royal Free London Hospital, NHS, UK Fellowship in Echocardiography Ex. House Physician, Cardiology Department NRS Medical College & Hospital

Lab No. : SLK/25-03-2023/SR7450761



Lab No. : SLK/25-03-2023/SR7450761

Patient Name : HARENDRA KUMAR Ref Dr. : Dr.MEDICAL OFFICER

Age : 36 Y 8 M 24 D

Gender: M Report Date: 27/Mar/2023 05:44PM



X-RAY REPORT OF CHEST (PA)

Lab Add.

Collection Date:

Visualised lung fields show no significant abnormality.

Domes of the diaphragm appear expiratory in position with normal CP angles and normal cardiac size.

Please correlate clinically.

DR. SUBHADRO GHOSE

MD, CONSULTANT RADIOLOGIST

Lab No. : SLK/25-03-2023/SR7450761 Page 9 of 9

SURAKSHA DIAGNOSTIC, RAJARHAT, KOLKATA. BIO-RAD VARIANT TURBO CDM 5.4 s/n 15893

PATIENT REPORT V2TURBO_A1c_2.0

Patient Data Analysis Data

Sample ID: D02135122075 Analysis Performed: 25/MAR/2023 14:46:07

 Patient ID:
 SR7450761
 Injection Number:
 10499U

 Name:
 Run Number:
 237

 Physician:
 Rack ID:
 0003

 Sex:
 Tube Number:
 3

DOB: Report Generated: 25/MAR/2023 15:02:39

Operator ID: ASIT

Comments:

	NGSP		Retention	Peak
Peak Name	%	Area %	Time (min)	Area
A1a		0.9	0.156	21946
A1b		1.5	0.217	36466
LA1c		1.7	0.396	41127
A1c	4.9		0.502	102288
P3		3.3	0.788	80551
P4		1.2	0.866	28351
Ao		87.3	0.985	2141273

Total Area: 2,452,002

<u>HbA1c (NGSP) = 4.9 %</u> HbA1c (IFCC) = 30 mmol/mol

